Real-world effectiveness and safety of tralokinumab in moderate-to-severe atopic dermatitis with malignancy, chronic infections, and multimorbidity [0.03%]
特拉鲁单抗治疗伴有恶性肿瘤、慢性感染和多种合并症的中重度特应性皮炎的有效性和安全性：真实世界证据
Francisco Javier Melgosa Ramos,Pedro Mercader,Sergio Santos Alarcón et al.
Francisco Javier Melgosa Ramos et al.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD) and significant comorbidities are frequently excluded from randomized clinical trials, limiting the applicability of evidence to these clinically compl...
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis [0.03%]
阿布司替尼治疗中至重度特应性皮炎的疗效和安全性：变量剂量与连续剂量的汇总分析
Jonathan I Silverberg,Eric L Simpson,Saleem A Farooqui et al.
Jonathan I Silverberg et al.
Introduction: Signs and symptoms of atopic dermatitis (AD) can fluctuate over time, necessitating a flexible dosing treatment approach for long-term management. This study evaluated the long-term efficacy and safety of va...
The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa-A Narrative Review [0.03%]
炎性生物标志物在银屑病、特应性皮炎和汗腺炎的疾病严重程度和治疗反应中的作用-叙述性综述
Julia Alicja Lewandowska,Agnieszka Owczarczyk-Saczonek
Julia Alicja Lewandowska
Chronic inflammatory skin diseases (CISDs) such as psoriasis (PsO), atopic dermatitis (AD), and hidradenitis suppurativa (HS) involve both cutaneous and systemic immune dysregulation, whereas commonly used scores rely largely on subjective ...
Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial [0.03%]
鲁索利替尼乳膏（HDM3010）治疗成人结节性痒疹的安全性、药代动力学和疗效：一项一期/二期随机双盲vehicle对照多中心临床试验
Chao Wu,Xuping Niu,Xiaohua Wang et al.
Chao Wu et al.
Introduction: Prurigo nodularis (PN) is a chronic inflammatory dermatosis with severe, persistent pruritus and limited effective therapies. Janus kinase (JAK) inhibition has emerged as a targeted strategy for PN. ...
Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel [0.03%]
慢性顽固性瘙痒诊疗的专家共识及治疗建议
Pedro Mendes-Bastos,Inês Lobo,Gilberto Pires da Rosa et al.
Pedro Mendes-Bastos et al.
Objective: Chronic prurigo (CPG) is a chronic neuroinflammatory skin disease characterized by persistent itch, repeated scratching, and the presence of multiple skin lesions. CPG is a highly burdensome disease that signif...
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial [0.03%]
III期DELTA 2随机对照双盲试验：使用德路佳软膏治疗严重手部湿疹患者时，最大化的德路佳用药量可使系统暴露最小化
Melinda Gooderham,Christopher G Bunick,JiaDe Yu et al.
Melinda Gooderham et al.
Introduction: Delgocitinib cream is a topical pan-Janus kinase inhibitor approved for adults with moderate to severe Chronic Hand Eczema (CHE) in the USA, Canada, European Union, and multiple other countries. Here, we ass...
Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial [0.03%]
risankizumab与deucravacitinib治疗中度斑块状银屑病成人患者：IMMpactful研究的16周结果
Nina Magnolo,Jennifer Soung,John Frew et al.
Nina Magnolo et al.
Introduction: Risankizumab (RZB) and deucravacitinib (DEU) are both approved for the treatment of moderate-to-severe psoriasis. Physicians value head-to-head comparisons between available therapies to make evidence-based ...
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial [0.03%]
TYK2选择性抑制剂扎索西替尼(TAK-279)用于治疗中重度斑块状银屑病患者的II期临床研究：事后分析
Nada Elbuluk,April W Armstrong,Ronald Vender et al.
Nada Elbuluk et al.
Introduction: Zasocitinib (TAK-279) is an investigational, once daily, oral, allosteric, highly selective, and potent tyrosine kinase 2 inhibitor. Post hoc analyses of a 12-week phase IIb trial in patients with moderate-t...
Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: Post Hoc Analysis of Pooled Data from Two Phase III Clinical Trials [0.03%]
基于机器学习的尼莫利珠单抗长期疗效预测：两项III期临床试验汇总数据的事后分析
Makoto Kawashima,Tomoya Maeda,Kotaro Iwasaki et al.
Makoto Kawashima et al.
Introduction: Nemolizumab is a humanized monoclonal antibody that specifically inhibits the receptor for interleukin-31, the major pruritogen in atopic dermatitis (AD). While the patient profile associated with the early ...
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial [0.03%]
阿普利玛斯改善短病程儿童银屑病患者皮损结果：SPROUT III期临床试验52周结果摘要
Richard G Langley,Lisa Arkin,Loretta Fiorillo et al.
Richard G Langley et al.
This is a summary of the original article "Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial". Enrolled patients were aged 6-17 years with moderate to ...